Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nuwellis Inc (NUWE) vs TJX Companies Inc (TJX) Price & Performance

Nuwellis IncTrade
TJX Companies IncTrade

Price performance (Past 24H)

Key statistics

Nuwellis Inc vs TJX Companies Inc — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while TJX Companies Inc trades at $139.23 (market cap $152.62B). The key difference: TJX Companies Inc is far larger — about 69372.7× Nuwellis Inc's market cap, and TJX Companies Inc pays a 1.38% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and TJX Companies Inc for 97 Days on average.

NUWETJX
Market Cap
$2.20M$152.62B
Volume
121,5448,079,794
Sector
HealthConsumer Cyclical
52-Week High
$146.65$168.41
52-Week Low
$0.68$122.84
Typical Hold Time
26 Days97 Days
Enterprise Value
-$1.52M$160.93B
Dividend Yield
—1.38%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nuwellis Inc

NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.

The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.

TJX Companies Inc

TJX trades at $138.70, down slightly by 0.07% on the day, with a bullish technical signal from moving averages but overbought RSI readings near 75. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $56.36 billion and $4.86 billion in 2025, respectively, while maintaining a robust ROE of 62.17%.

Wall Street analysts are overwhelmingly bullish, with an 84.9% buy rating and a consensus price target of $174.15, implying 28% upside. Key risks include competitive pressures in off-price retail and potential macroeconomic headwinds affecting consumer spending. The stock's valuation at a P/E of 25.69 appears justified by its earnings growth trajectory.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NUWE
2% Buy98% Sell
Avg holding period · 26 Days
TJX
100% Buy0% Sell
Avg holding period · 97 Days

Top news

Latest headlines on both assets

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE →

About TJX Companies Inc

TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.

Read more on TJX →